Oily Skin: Labs, Causes, and Next Steps

Why Sebaceous Glands Overproduce Oil

Sebaceous glands respond to circulating androgens through intracellular 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). DHT binds androgen receptors on sebocytes and stimulates both gland enlargement and lipid synthesis. This is not a disease state in every case. Some people simply have more androgen receptors per unit area of facial skin.

The density of sebaceous glands on the face ranges from 400 to 900 per square centimeter on the forehead and nose 1. Each gland can produce sebum at rates varying fivefold between individuals with identical serum androgen levels. Genetic polymorphisms in the androgen receptor gene (AR) on the X chromosome partially explain this variation. A 2009 study in the Journal of Investigative Dermatology found that shorter CAG repeat lengths in the AR gene correlated with higher sebum output (r = -0.34, P = 0.008) 2.

Beyond genetics, insulin and insulin-like growth factor 1 (IGF-1) amplify androgen signaling at the sebocyte level. Hyperinsulinemia increases ovarian and adrenal androgen production while reducing sex hormone-binding globulin (SHBG), which leaves more free testosterone available to stimulate glands 3. This is why patients with insulin resistance often develop oily skin years before metabolic syndrome becomes clinically apparent.

The Lab Panel That Identifies the Driver

A focused hormonal workup distinguishes treatable endocrine causes from constitutional seborrhea. The initial panel should include free testosterone (by equilibrium dialysis, not analog assay), total testosterone, DHEA-S, fasting insulin with glucose (to calculate HOMA-IR), and SHBG.

For premenopausal women, draw labs on cycle days 3 through 5 for accurate interpretation. A free testosterone above 5 pg/mL or DHEA-S above 350 mcg/dL suggests androgen excess requiring further workup 4. The Endocrine Society's 2018 guidelines recommend these thresholds as screening values before pursuing imaging or more specialized testing 5.

HOMA-IR above 2.5 indicates insulin resistance sufficient to drive sebaceous overactivity even with normal androgen levels. A 2016 study in the Journal of the European Academy of Dermatology found that 61% of women presenting with isolated seborrhea (no acne, no hirsutism) had HOMA-IR values above 2.0, compared to 22% of age-matched controls (P < 0.001) 6.

Additional labs to consider based on clinical context: thyroid-stimulating hormone (TSH) if skin texture changes accompany oiliness, prolactin if menstrual irregularity is present, and 17-hydroxyprogesterone if late-onset congenital adrenal hyperplasia (LOCAH) is suspected. LOCAH accounts for 1-5% of androgen excess in women and is frequently missed 7.

When Oily Skin Signals Something Deeper

Not every oily face needs a workup. Constitutional seborrhea in a 22-year-old with no other signs of androgen excess is normal physiology. Red flags that warrant investigation include: sudden onset of oiliness after age 30, concurrent hirsutism or hair thinning, menstrual irregularity, rapid weight gain concentrated in the trunk, or acanthosis nigricans.

Dr. Ricardo Azziz, former president of the American Society for Reproductive Medicine, has stated: "Isolated seborrhea in the absence of acne or hirsutism is often dismissed, but in my experience it can be the earliest clinical marker of evolving PCOS, sometimes preceding the classic phenotype by 3 to 5 years" 8.

In the Rotterdam criteria framework, oily skin alone does not qualify as "clinical hyperandrogenism." However, the 2023 International PCOS Guidelines from Monash University acknowledge that seborrhea may serve as a supporting sign when combined with biochemical hyperandrogenism 9. For men, new-onset seborrhea with elevated testosterone should prompt evaluation of exogenous androgen use, testicular tumors, or adrenal pathology depending on which androgen fraction is elevated.

Topical Treatments That Reduce Sebum Output

Retinoids remain the most effective topical class for reducing sebaceous gland activity. Adapalene 0.3% reduced casual sebum levels by 55% at 12 weeks in a randomized controlled trial of 150 subjects with oily, acne-prone skin (P < 0.001 vs. vehicle) 10. Tretinoin 0.025-0.05% produces similar effects but with more irritation during the first 4 weeks.

Niacinamide (vitamin B3) at 2-4% concentration offers a gentler alternative. A double-blind study published in the International Journal of Cosmetic Science demonstrated a 23% reduction in sebum excretion rate after 4 weeks of twice-daily niacinamide 2% application compared to vehicle (P = 0.01) 11. The mechanism involves inhibition of lipid synthesis within sebocytes without affecting gland size.

Green tea polyphenols (epigallocatechin gallate, EGCG) applied at 3% concentration reduced sebum production by 27% in a split-face trial over 8 weeks 12. EGCG inhibits 5-alpha reductase type 1 locally, reducing DHT formation at the gland level.

A practical layering approach for moderate seborrhea: niacinamide 4% serum in the morning under a non-comedogenic SPF, retinoid (adapalene 0.1% or tretinoin 0.025%) in the evening. Expect noticeable sebum reduction within 3-4 weeks. If no improvement at 8 weeks, systemic therapy discussion is reasonable.

Systemic Options for Hormonal Seborrhea

When labs confirm androgen excess or insulin resistance as the driver, targeted systemic therapy addresses the root cause rather than compensating at the skin surface.

Spironolactone blocks androgen receptors and inhibits 5-alpha reductase. At 100 mg daily, it reduces facial sebum excretion by 30-50% within 3 months 13. The drug is only appropriate for women (teratogenic to male fetuses). Side effects include breast tenderness (15-20%), irregular menses (10-15%), and mild hyperkalemia (check potassium at 4-6 weeks). Dr. Julie Harper, dermatologist and past president of the American Acne and Rosacea Society, has noted: "Spironolactone is my first systemic choice for women over 25 with hormonal oiliness who aren't planning pregnancy in the near term. The sebum reduction is reliable and the safety profile over decades of use is well-established."

Combined oral contraceptives (COCs) containing anti-androgenic progestins (drospirenone, cyproterone acetate, or dienogest) reduce free testosterone by 40-60% through SHBG elevation 14. Yaz (ethinyl estradiol 20 mcg / drospirenone 3 mg) is FDA-approved for acne in women, and the sebum reduction is a direct mechanistic consequence. Effect onset takes 2-3 cycles.

Metformin (1500-2000 mg daily) addresses insulin-driven seborrhea by reducing hyperinsulinemia and its downstream effects on androgen production. In a randomized trial of 100 women with PCOS, metformin 1500 mg daily reduced sebum casual levels by 35% at 6 months compared to placebo (P = 0.003) 15. This option is particularly relevant when HOMA-IR is elevated.

Isotretinoin at low dose (10-20 mg daily or 0.3 mg/kg) provides the most dramatic sebum reduction of any available therapy. A 2014 study in the Journal of the American Academy of Dermatology showed that isotretinoin 0.5 mg/kg reduced sebum excretion by 80% within 6 weeks, with effects persisting 12-18 months after discontinuation in 60% of patients 16. Low-dose protocols (10 mg every other day or 20 mg daily) achieve 50-60% sebum reduction with fewer mucocutaneous side effects.

Diet, Lifestyle, and Adjunctive Measures

High-glycemic diets increase insulin and IGF-1, both of which amplify sebaceous gland activity. A 12-week randomized trial (N=43) found that a low-glycemic-load diet reduced sebum production by 12% compared to a control diet, with parallel reductions in fasting insulin 17. The effect is modest but additive with pharmacotherapy.

Dairy consumption, particularly skim milk, correlates with increased sebum output in observational studies. The proposed mechanism involves dairy-derived IGF-1 and leucine, which activate mTORC1 signaling in sebocytes 18. A 3-month dairy elimination trial is reasonable for patients motivated to test dietary modification before starting medication.

Zinc supplementation at 30 mg elemental zinc daily (as zinc gluconate or picolinate) reduced sebum output by 29% in a 12-week placebo-controlled trial of 54 subjects with oily skin 19. Zinc inhibits 5-alpha reductase and has mild anti-inflammatory properties at the sebaceous unit. Check serum copper if supplementing beyond 3 months, as zinc competes with copper absorption.

Omega-3 fatty acids (EPA 1-2 g daily) may modulate sebaceous lipid composition toward less inflammatory profiles, though direct sebum-quantity reduction is not well demonstrated in controlled trials. The evidence is stronger for reducing inflammatory acne lesions than for reducing overall oiliness.

Building a Step-by-Step Clinical Plan

The diagnostic and treatment pathway should follow a logical sequence based on severity and lab findings.

Step 1: Assess severity and duration. Oily skin present since puberty with no worsening and no androgen-excess signs is likely constitutional. New-onset or worsening seborrhea in adults warrants lab evaluation.

Step 2: Obtain baseline labs. Free testosterone, DHEA-S, SHBG, fasting insulin, fasting glucose. Add 17-OHP if DHEA-S is elevated. Add prolactin and TSH if clinical context warrants.

Step 3: Initiate topical therapy. Begin retinoid (adapalene 0.1-0.3% or tretinoin 0.025%) with niacinamide 4%. Reassess at 8-12 weeks.

Step 4: Address root cause systemically if identified. Insulin resistance: metformin 500 mg titrated to 1500-2000 mg. Androgen excess in women: spironolactone 50-100 mg or COC with anti-androgenic progestin. Consider low-dose isotretinoin for severe, treatment-resistant seborrhea regardless of sex.

Step 5: Monitor and adjust. Recheck labs at 3 months on systemic therapy. Target free testosterone into mid-normal range, HOMA-IR below 2.0. Adjust doses based on clinical response and tolerability.

For patients starting isotretinoin, baseline and monthly labs include complete metabolic panel, lipid panel, and pregnancy test (if applicable). Most patients on low-dose protocols (10-20 mg daily) maintain normal lipids and liver function, but monitoring remains standard of care per AAD guidelines 20.

What to Expect: Timelines for Improvement

Topical retinoids reduce measurable sebum within 4-6 weeks, with maximum effect at 12 weeks. Spironolactone takes 6-12 weeks for noticeable skin-surface changes due to the sebaceous gland turnover cycle of approximately 30 days. Isotretinoin works fastest among systemic agents, with patients reporting reduced oiliness within 1-2 weeks and measurable 80% reduction by week 6.

After isotretinoin discontinuation, sebum production gradually returns in about 40% of patients over 12-24 months. The remaining 60% maintain reduced sebum for at least 18 months, and a subset experience permanent gland atrophy 16. Repeat low-dose courses are safe and commonly prescribed for relapse.

Metformin's sebum-reducing effects plateau at 3-6 months. If HOMA-IR normalizes but oiliness persists, the contribution of insulin resistance was likely partial, and adding an anti-androgen or retinoid addresses the residual component. Combination therapy (metformin plus spironolactone) is well-tolerated and addresses both pathways simultaneously in women with PCOS-driven seborrhea.